Today we have sent out a media release announcing some very exciting news. MVMD has filed a novel cancer patent and is proceeding with three separate pre-clinical trials with specialized third-party cancer research organizations in the areas of triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
Almost everyone has a story related to the devastating impact of cancer within their family or in their network of friends and relatives. I lost my own mother-in-law four years ago to small lung carcinoma and have witnessed the painful impact firsthand. According to the World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The World Cancer Day foundation estimates the total annual economic cost of cancer at approximately US$1.16 trillion.
Our cancer studies will be the first of their kind ever conducted with human grade solubilized Ivermectin anywhere in the world and are being conducted to prove the utility of Ivectosol™ to synergize and improve various cancer regimens currently in use and as a potent enhancer of current immunotherapies and chemotherapies for difficult to treat cancers. As we communicated in the media release, we expect to start to see some initial readouts later in June with final results later in July this summer.
Leading up to the implementation of pre-clinical trial cancer research, MVMD has been extensively researching the drug ivermectin, including its impact on cancer. There are numerous third-party research articles that prove ivermectin has powerful antitumor effects in a variety of cancer cells and promotes programmed cancer cell death, including apoptosis, autophagy, and necrosis. The research also identifies how ivermectin has been shown to inhibit tumor stem cells and reverse multidrug resistance.
As Mike Farber, our Director of Life Sciences outlines effectively, the extensive research supporting the drug ivermectin as effective in the inhibition of proliferation, metastasis, and angiogenic activity in a variety of cancers, and as an initiator of immunogenic cell death, is overwhelming.
“Imagine what is possible when you have the world’s only human injectable form of ivermectin that can be directly injected into a tumor or provided through more bio-available forms such as intravenously. We believe this will be groundbreaking research with near-immediate application to be able to proceed directly to human trials based on the safety and efficacy of ivermectin.”
As I have outlined many times, ivermectin is a Nobel prize winning, global blockbuster drug with unprecedented potential. Overcoming its number one limitation of solubility using FDA approved excipients has opened up significant applications across multiple human and animal health lanes for Mountain Valley MD and our partners.
You can read the full media release on our website at https://www.mountainvalleymd.com.
We remain very proud to be leading this journey to make this world a better place, to serve as change makers and to drive towards our goal of bringing more life and helping to ensure there is less death and suffering. Driving innovation in cancer research to support positive outcomes for increased survival rates, productivity, and improved quality of life for the global population is directly aligned with MVMD’s mission. We couldn’t be more honoured to drive forward this important work.
Thanks for joining us on this journey to reimagine what is possible.
President & CEO, Mountain Valley MD